Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.

Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing

September 25, 2023

Pharmaceuticals

Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.

Biosynth Carbosynth Acquires Pepscan

July 4, 2022

Biotechnology

Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Gannet BioChem Acquires Laysan Bio

January 22, 2026

Biotechnology

Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.

Biosynth Carbosynth Acquires Aalto Bio Reagents

May 26, 2022

Biotechnology

Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.